EYECYTE
EyeCyte, Inc. is working with Pfizer's Bioinnovation and io therapeutics Center and The Scripps Research Institute to develop novel therapeutics to treat neovascular and degenerative retinal disease.
EYECYTE
Industry:
Biotechnology Health Care Therapeutics
Founded:
2005-01-01
Address:
La Jolla, California, United States
Country:
United States
Website Url:
http://www.eyecyte.com
Total Employee:
1+
Status:
Active
Contact:
858-453-5800
Email Addresses:
[email protected]
Total Funding:
3 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Content Delivery Network Font Awesome Domain Not Resolving
Similar Organizations
Aegerion Pharmaceuticals
Aegerion Pharmaceuticals engages in the development of therapeutics and pharmaceuticals to treat cardiovascular and metabolic diseases.
American Biogenetic Sciences
American Biogenetic Sciences is the development of diagnostic tests for the detection of cardiovascular and infectious disease
BMdr
BMdr is engaged in the research and development of therapeutics and products for the treatment and prevention of eye diseases.
Gene Sciences, Inc.
Gene Sciences Inc. is developing novel DNA targeted therapeutics for the treatment of human genetic diseases.
Sarentis Therapeutics
Sarentis Therapeutics engages in the development of therapeutics for the treatment of pain.
Current Employees Featured
Founder
Investors List
Pfizer Venture Investments
Pfizer Venture Investments investment in Series A - EyeCyte
Official Site Inspections
http://www.eyecyte.com
- Host name: 45.42.41.25
- IP address: 45.42.41.25
- Location: McHenry United States
- Latitude: 42.3275
- Longitude: -88.2918
- Metro Code: 602
- Timezone: America/Chicago
- Postal: 60050
More informations about "EyeCyte"
EyeCyte - Crunchbase Company Profile & Funding
Organization. EyeCyte . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. EyeCyte is engaged in the development of …See details»
My EyeCyte Doctor Near Me - EyeCyte
EyeCyte offers amniotic membrane for dry eye therapy on ocular surface for chronic dry eye, scratched cornea treatment, cornea tears, ocular amniotic membrane contact lens for chlamydial conjunctivitis in eye infections , atopic …See details»
EyeCyte, Inc. Secures Series A Funding from Pfizer
Jun 22, 2008 “EyeCyte is delighted to have attracted Pfizer as an investment partner”, said Mohammad A. El-Kalay, Ph.D., president and Chief Executive Officer, EyeCyte. “We are very …See details»
EyeCyte Company Profile | Management and Employees List
EyeCyte, Inc., an early stage stem/progenitor cell-based ophthalmology research and development company based in La Jolla, California. The company will exploit a decade of …See details»
EyeCyte - Org Chart, Teams, Culture & Jobs | The Org
View EyeCyte's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
EyeCyte - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Jun 23, 2008: Series A - …See details»
EyeCyte - Products, Competitors, Financials, Employees, …
EyeCyte is a healthcare company focused on regenerative medicine within the ocular health sector. Use the CB Insights Platform to explore EyeCyte's full profile. EyeCyte - Products, …See details»
EyeCyte - Crunchbase
EyeCyte is engaged in the development of therapeutics for the treatment of neovascular and degenerative retinal diseases.See details»
EyeCyte - Overview, News & Similar companies | ZoomInfo.com
EyeCyte will seek to translate these pre-clinical observations into the clinic by engineering a cGMP process to commercialize cell-based therapies for ophthalmic disease. Dr. El-Kalay and …See details»
EyeCyte Obtains $3M from Pfizer through Series A Round
Jun 23, 2008 EyeCyte secured a $3 million series A financing through an agreement with Pfizer. The backing will reportedly support the company into 2010. EyeCyte focuses on …See details»
Pfizer to invest in adult stem-cell treatment for eyes
Jun 25, 2008 EyeCyte will receive about $3 million from Pfizer, which in return has the right of first refusal regarding the new company’s products. In animal experiments, adult stem-cells …See details»
Team - EyeCyte
Our Team Our team is here for you ! Leadership Trained to serve, heart to care and passion to change the world our leadership team believes in A RISING TIDE LIFTS ALL BOATS …See details»
Doctors - EyeCyte
Welcome to EyeCyte Welcome to the Future OF OCULAR CARE! OUR TECHNOLOGY, PRODUCTS, TRAINING, NATIONAL BRANDING WITH YOUR EXPERTISE CAN CHANGE …See details»
Pfizer bankrolls a stem cell start-up - Fierce Biotech
Jun 24, 2008 And the new company, EyeCyte, will be responsible for advancing that research into the clinic. Pfizer is investing $3 million in the company and has an option to buy it if …See details»
The cell that might save sight | Nature Reports Stem Cells
Jun 11, 2009 EyeCyte is developing his work as a cellular therapy for diabetic retinopathy. Similarly, StemCells in Palo Alto, California, is betting on fetal neural stem cells to migrate to …See details»
EyeCyte, Inc. Secures Series A Funding from Pfizer
Jun 24, 2008 Under the terms of the deal, Pfizer has invested $3 million in Series A Preferred shares of EyeCyte. Pfizer will be the sole pharmaceutical partner and will have an Advisory …See details»
EyeCyte - Contacts, Employees, Board Members, Advisors & Alumni
Organization. EyeCyte . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 1. About. EyeCyte has 1 …See details»
EyeCyte, Inc. Secures Series A Funding From Pfizer
Jun 24, 2008 “ EyeCyte is delighted to have attracted Pfizer as an investment partner ” ... and believe that Pfizer shares our goal of building a premier ophthalmology research and …See details»
Medical optometrists - EyeCyte
A survey from Eyecyte chose over 90% of optometrist surveyed do not do ocular amniotic patches as part of their clinical or treatment procedures. That same study showed that 91% of the …See details»
Eyecyte-RPE™ in Eye Diseases and Age-Related Macular ... - ICH GCP
Apr 15, 2024 The results of the pre-clinical safety and efficacy studies with Eyecyte-RPE™ have been very encouraging. It has been shown to provide significant beneficial effects on the …See details»